Epithelial ovarian cancer is a highly heterogenous, metastatic and lethal disease. The presence 46 of CD8 + T cells within ovarian tumors is positively associated with overall patient survival. 47
Ovarian cancer is the most lethal malignancy of the female reproductive tract 1 . Conventional 89 therapy involving cytoreductive surgery and chemotherapy are 90% effective when cancer is 90 diagnosed at the early stage when it is still restricted to one or both ovaries. Unfortunately, most 91 ovarian cancer cases are diagnosed at stage III or IV when the cancer has metastasized and the 92 diagnosis in these patients result in a 30% 5-year survival rate 2 . To develop efficacious therapies 93 for metastatic ovarian cancer, we need to define the cellular heterogeneity and the 94 transcriptional state within the tumor microenvironment. Immunohistochemical staining and 95 flow cytometry have been useful in categorizing the cell types based on specific cell surface 96 markers but mask intra-cellular heterogeneity. Bulk RNA profiling has been used to categorize 97 high grade serous ovarian carcinoma (HGSOC), the most common and lethal histotype of ovarian 98 cancer, into molecular subtypes 3,4 . However, bulk RNA sequencing averages gene expression and 99 fails to identify the respective contribution of cell subsets. Alternatively, single cell RNA 100 sequencing (scRNA-seq) has emerged as a powerful tool to interrogate tumor composition, 101
revealing previously uncharacterized cellular heterogeneity and gene regulatory networks at 102 single cell resolution [5] [6] [7] [8] [9] [10] . Recently, a scRNA-seq study, investigated the heterogeneity in the 103
proposed cell of origin of HGSOC and revealed a high epithelial-mesenchymal transition (EMT) 104
high subtype associated with poor prognosis 11 . These transcriptomic studies have focused on 105 ovarian cancer cells; however, the tumor microenvironment is made up of other cell types that 106
can affect patient stratification, targeted treatment and outcome. 107 108
The omentum is mainly an adipose tissue in the peritoneal cavity containing aggregates of 109 immune cells in areas called milky spots 12 . These milky spots act similar to lymph nodes, collecting 110 and responding to antigen within the peritoneal cavity. Interestingly, ovarian cancer cells 111 preferentially colonize adipose tissue with milky spots in the peritoneal cavity 13 . Additionally, 112
adipocytes provide adipokines and act as a source of energy for ovarian cancer cells 14 . These 113 factors prime the omentum as a premetastatic niche for ovarian cancer. The initial presence of 114 ovarian cancer cells in the omentum leads to a recruitment of macrophages into the milky spots 115 without anti-tumor effects. Contrastingly, the presence of tumor infiltrating CD8 + T cells in both 116 the ovary and omentum is associated with significantly longer overall survival 15 . However, 117 checkpoint inhibitors, a cancer immunotherapeutic approach, aimed at restoring CD8 + T cell 118 function have had a low response rate 15 . We therefore need a better understanding of the tumor 119 microenvironment to improve patient response rate to cancer immunotherapy. 120 121
In this current study, we use Drop-seq technology to examine the cells within omental tumors 122 from 6 patients with different histotypes of ovarian cancer. We identified 12 cell clusters and 123 patient samples were stratified into two groups based on immune signatures: Ovarian cancer tissues obtained from the anatomic pathology department were fixed overnight 144 in 4% formaldehyde at 4 0 C. After serial dehydration, the tissues were embedded in paraffin and 145 cut into 5 µm thick sections. Histological evaluation was done with hematoxylin and eosin (H&E). 146
Immunohistochemical staining was performed to confirm the presence of cytokeratin-7 147 (Thermofisher), pan-vimentin (DAKO), CD45 (Agilent), CD3 (Human Envision) and CD19 (Abcam)  148 cells. Briefly, sections were deparaffinized and rehydrated using xylene and serial dilutions of 149
EtOH in distilled water. Tissue sections were incubated in citrate buffer, pH 6 and heated in a 150 microwave oven. Anti-cytokeratin-7 (1:1000), anti-vimentin (1:100), anti-CD45 (1:100), anti-CD3 151
(1:100), and anti-CD19 (1:200) antibodies were applied on tissue sections with one-hour 152 incubation at room temperature in a humidity chamber. The antigen-antibody bindings were 153 detected with labeled polymer-HRP Envision system (DAKO, K4007) and DAB+ chromogen 154 (DAKO, K3468) system. Tissue sections were briefly immersed in hematoxylin for counterstaining 155 and were covered with cover glasses. 156 157
Tissue digestion, red blood cell lysis and dead cell removal 158 159
Ovarian cancer tissue was transported in DMEM/F12 containing 10% FBS and 1% P/S (10% 160 DMEMF/12) on ice from the anatomic pathology department to the laboratory. The tissue was 161 minced manually with a scalpel and enzymatically digested using 1.5 mg/ml collagenase IV 162 (Sigma-Aldrich), 1 mg/ml hyaluronidase (Sigma-Aldrich) and 500 µg/ml DNase I (GoldBio) in 163
Hank's balanced salt solution (HBSS) in a 37 0 C shaker (200 rpm) for 0. to maximize the sequencing depth (PT-3401 was sequenced three times). Each run produced 195 paired-end reads, with Read 1 representing the 12 bp cell barcode and six bp unique molecular 196 identifier (UMI), and Read 2 representing a 60 bp mRNA fragment. Paired-end reads from the 197 same samples were merged to generate six paired-end fastq files. A snakemake pipeline was 198 applied to each sequencing run and produce a count matrix representing the gene expression in 199 every cell 19 . Individual count matrices were produced for each of the six patients after accounting 200 for UMI duplicates. 201 202
The individual count matrix was produced for each patient with a total number of six count 203 matrices. The summarized counts for each gene were inferred based on both exon and intron 204 reads to produce the gene expression matrix per sample. Expression matrices of six ovarian 205 cancer samples from the metastatic sites in the omentum were generated. To select high quality 206
cells, we applied a filter based on the number of genes detected per cell. Prior to filtering, each 207
sample produced approximately 5000 cells. Based on the median number of genes captured, cells 208 with less than 800 genes were removed from the data sets. For lower quality samples, the 209 threshold was lowered to 600 or 700 as shown in Table 2 . We followed a standardized pipeline 210 using single cell analysis tool suite, Seurat v3.0.2 20,21 . A global-scaling logarithmic normalization 211
method was applied to all samples 21 that normalizes the feature expression counts for each cell 212 by the total expression counts, multiplies by a scale factor of 10,000 (TP10K), and natural-log 213 transforms, as ln(TP10K+1). Each normalization matrix was then scaled by a linear transformation 214 to center the mean gene expression of cells and normalized the gene expression variance. The 215 most variable genes were extracted for principal component analysis (PCA). We applied PCA on 216 the normalized expression matrix with the most variable genes to extract the top 50 components 217 in the data, followed by a heuristic elbow plot on the variance explained of each PC. We selected 218 the number of top variant PCs based on the elbow plot which varies from 10 to 20 depending on 219 the sample. The top PCs were used in further exploration of the data, such as UMAP /tSNE 220 dimension reduction, construction of K-nearest neighbor graph, etc. For analysis that included 221 multiple samples, integration through anchoring 22 was applied. Note that a subset of genes, 222 usually highly variable ones, was selected to perform the integration, where the integrated gene 223 expression matrix has a lesser number of features (genes) than the original gene expression 224 matrix. The samples from multiple patients were integrated before classifying cell types. 225
Differential expression analysis was done through FindMarkers function in Seurat V3 using the 226
Wilcoxon Rank Sum test, and statistically significant markers were extracted for sub-populations 227 or contrast groups based on an adjusted p-value threshold of 0.05. We used dimension reduction 228 methods, UMAP 23 and tSNE 24 to generate 2D plots to visualize different cell populations in the 229 experiment. 230 231
Cancer subtype classification and correlation with The Cancer Genome Atlas 232 233
Four cancer subtypes-differentiated, immunoreactive, mesenchymal, and proliferative were 234 determined from bulk sequencing study on ovarian cancer 4 . Modular scores 25 were generated 235 between gene expression levels for each cell with upregulated marker signatures on the four 236 subtypes. The subtypes were then assigned to individual cells by the highest positive modular 237 score and if no positive modular scores were found, the subtype was considered undecided. 238 239 240
Cell type classification and correlation with CellAtlas 241 242
To assign cell types to individual cells, we used a bulk RNA sequencing data-set from 95 cell lines 243 collected by CellAtlas 26 , covering 33 major cell types in normal human tissue, including common 244 immune, endothelial, epithelial, fibroblast, mesodermal cells and so on. The cell lines can be 245 further divided into 60 subtypes. We inferred the similarity between individual cells in the categories which make certain cell types hard to identify. By leveraging prior knowledge from the 260 CellAtlas mapping, we were able to locate the relevant function categories for those cell types 261 and narrow down their marker genes efficiently 26 . Moreover, by the consensus of both GO and 262
CellAtlas analyses, we obtained higher confidence in classifying cell types in each patient sample. 263 264 We used the cell types obtained from CellAtlas correlation as baseline and curated cell-types 265 manually using canonical genes and functional association. Differentially expressed marker genes 266
were extracted from cell clusters. Cross-referencing was done between gene markers and known 267 canonical genes to the cell-types. Gene ontology and pathway enrichment was performed on 268 gene markers to provide additional evidence for cell-type assignment. there is an inverse relationship between ovarian tumor growth (cancer and cancer associated cell 285 growth) and adipocytes within the omentum 14 . Therefore, the area of tumor occupied by 286 adipocyte decreases with disease score 28 . To quantify the transformation of the omentum by 287 ovarian cancer cells, we used Imagescope, a digital histopathology software, to annotate and 288 calculate the area occupied by adipocytes in each patient sample on hematoxylin and eosin (H&E) 289 stained sections ( Figure 1A) . The area of adipocytes was reported as a percentage of the total 290 surface area of the sample and used as a measure of disease score ( Figure 1B) , similar to Pearce 291 et al. 28 We rated the patient samples from lowest to highest disease score; PT-5150, PT-3401, PT-292 6885, PT-3232, PT-4806, PT-2834 respectively. The percentage of cancer cells, stromal cells and 293 immune cells were quantified by immunohistochemistry (IHC) using antibodies against 294 cytokeratin-7 (CK-7), vimentin and CD45 antibodies ( Figure 1C-H) . There was a varying proportion 295 of each cell type across patients. Notably, we observed that malignant cells in some patients (PT-296 5150, PT-3232, PT-4806 and PT-2834) double stained for CK-7 and vimentin, suggesting active 297 epithelial-mesenchymal-transition ( Figure 1C-F) . In addition, the MMMT (PT-2834) sample had 298 two different types of malignant cells that stained separately for CK-7 and vimentin. We assessed 299 the relationship between the area of adipocytes and the cancer and stromal compartments and 300 only observed a positive correlation with CD45 + immune cells ( Supplementary Figure 1) . Notably, 301 we observed aggregation of immune cells closer to adipocytes and sparsely otherwise 302 throughout the rest of the tissue. Together, these data reveal patient variability in the cellular 303 transformation of tumors from the same pathological stage. 304 305 306
Generation of single cell data, cell clustering and cell type assignment 307 308
For Drop-seq experiments, tumors samples were enzymatically digested into a single cell 309 suspension and processed 16 . We integrated all six omental samples into a gene expression matrix 310 which contains the expression values of 9885 cells and 40947 genetic features such as protein 311
coding genes, pseudogenes, lncRNA, mapped from the GENCODE human reference genome 312 (version GRCh38). A minimum cut off of 600-800 genes per cell was set, as shown in Table 2 . 313
Hierarchical clustering was performed using resolution of 0.2 with 12 clusters detected 314 ( Supplementary Figure 2A) . Each cluster had cells from all samples ( Supplementary Fig. 2B ). The 315 cell types were assigned and curated by cell line correlation, canonical genes and functional 316 categories for the significantly differentially expressed genes on the detected clusters. 9 major 317 clusters out of 12 were identified with cell types (Figure 2A ). This included 1 cluster for malignant 318 epithelial cells, 1 cluster for fibroblasts, 1 cluster for mesenchymal stem cells, 1 cluster for 319 embryonic stem cells, 1 cluster for endothelial cells. Each patient sample had a varying proportion 320 of the 9 identified cell types/clusters ( Figure 2B ). Previous bulk mRNA and microRNA expression 321 studies have established 4 transcriptional subtypes of HGSOC 3,29 . To assign molecular subtypes, 322
we extracted gene sets defining each molecular subtype and applied them to our Drop-seq data. 323
At the single cell level, each molecular subtype is represented in every patient tumor sample 324 ( Figure 2C ). We further analyzed which cell type/cluster belonged to each molecular subtype. 325
The differentiated and proliferative subtypes were mainly made up of epithelial cells, 326 mesenchymal and immunoreactive subtypes were mainly made up of fibroblasts and immune 327 cells respectively suggesting that TCGA classification is reflective of the proportion of cells types 328 within each tumor ( Figure 2D ). 329 330
It has been suggested that the TCGA subtypes may be useful in specifically categorizing cancer 331 cells within a tumor. However, most of the cancer cells belonged to the differentiated, 332
proliferative and undecided subtype. Therefore, to determine patient-derived differences in 333 cancer cells that might be useful in personalizing therapy, we generated a heatmap from 334 differentially expressed genes from each patient. The expression profile of all patients appeared 335 similar in all patients except PT-2834 ( Figure 2E ). This patient was histologically diagnosed with 336
MMMT with chondrosarcomatous elements, also confirmed by our Drop-seq data 337 ( Supplementary Figure 3) . Next, the central cluster (epithelial cells) and connecting ESCs were 338 selected and assessed for known ovarian cancer cell markers with 7 clusters detected ( Figure 2F ). 339
PAX8 and MUC16, indicative of advanced disease, was expressed by multiple clusters 30,31 . Cluster 340 1 expressed vimentin along with high Ki-67 and PCLAF indicative of a proliferating population. 341
Cluster 5 also expressed PCLAF, a marker of proliferation, as well as FN1 and ZEB1, markers of 342
EMT. Cluster 6 highly expressed vimentin and Ki-67 along with comparatively lower expression 343 of EMT markers (ZEB1 and ZEB2), suggestive of cells undergoing mesenchymal to epithelial 344 transition ( Figure 3E ). Ovarian cancer stem cells marked by co-expression of CD33, CD44, CD117 345 and CD24 expression were not observed 32 . Cells in this cluster expressed IL-6 which correlates 346 with poor prognosis in ovarian cancer and TGF-b which induces an aggressive cancer 347 phenotype [33] [34] [35] [36] . These results reveal a snapshot of the heterogeneous processes that cancer cells 348 harness to progress disease. 349 350
Immune cellular profile of patient samples 351 352
To investigate the immune population in our patient samples, we selected the immune cells from 353 the six patient samples and they clustered into 4 main populations; T cells, B cells, plasma B cells 354 and monocytes/macrophages ( Figure 3A) . Similar samples were grouped by a dendrogram with 355 a major difference in T cell infiltration (Tinf) ( Figure 3B) PT-3233) had higher disease score. During the initial phase of metastasis, macrophages are 358 recruited from the peritoneal cavity without any anti-tumor effect on the cancer cells 37,38 . To 359 assess the differences in the macrophage population, we performed unsupervised clustering on 360 both groups separately ( Figure 3C&D ). Both groups had a CD14 + CD16 + CD163 + CD204 + cluster 361 reminiscent of tumor associated macrophages or TAMs (Figure 3E&F, Supplementary Figure 4) . 362
In the low Tinf group, there was also an immature FLT3 + population. These FLT3 + progenitors can 363 differentiate into osteoclasts, dendritic cells, microglia and macrophages 39 . Other clusters in the 364 high Tinf group included a CD274 + cluster, suggesting a regulatory population similar to MDSCs 365
and an IRF8 + cluster induced in the presence of IFN-g and promotes the formation of 366 autophagosome ( Figure 3E&F, Supplementary Figure 4 ) 40 . The final cluster highly expressed 367 NR1H2 which inhibits inflammatory genes in macrophages 41,42 . This clustering analysis reveals 368 phenotypically distinct macrophages present in the tumor in addition to the established TAMs. 369 370
Differences in T cell clustering and subtype analysis 371 372
To reveal the functional subtypes of T cells and any difference in the low Tinf versus high Tinf group, 373
we clustered 136 and 820 T cells respectively ( Figure 5A&B ). A total of 3 and 4 transcriptionally 374 distinct clusters emerged from low Tinf and high Tinf T cells respectively. The top genes revealed 375 clusters similar to previously described T cell phenotypes in breast cancer, including CD4 + IL7R + , 376
CD4 + FOXP3 + , resident memory CD8 + T cells (CD8 + Trm cells) and one population described in lung 377 cancer with high granulysin expression CD4 + GNLY + (Figure 5C-F, Supplementary Figure 5 ) 43,44 . 378
Both groups had CD8 + Trm cells which expressed IFN-g, CD4 + IL7R + and CD4 + FOXP3 + T cells. The 379
high Tinf group had an extra CD4 + GNLY + cluster. Contrastingly, GNLY was expressed in the low Tinf 380 group by CD8 + Trm cluster ( Figure 5C&D ). TOX was highly expressed by the CD8 + Trm and the 381 CD4 + GNLY + clusters in the high Tinf group as compared to the low Tinf group ( Figure 5E&F) . These 382 TOX + T cells persist during chronic infection and TOX is expressed on the CD8 + T cells that are 383 reactivated in response to PD-L1 immunotherapy 45, 46 . Layilin, a previously described marker of 384 exhaustion was mainly expressed by the CD4 + FOXP3 + cluster ( Figure 5E&F ). These data suggest 385 that scRNA-seq is capable of determining patients that will benefit from novel therapy. 386 387
Transcriptionally distinct plasmablasts cluster in high Tinf group 388 389
The high Tinf group had an accompanying high B cell signature ( Figure 3B ). To investigate the B 390 cell subtypes in our samples, naïve B cells and plasma cells were clustered yielding 4 and 2 391 clusters in high Tinf and low Tinf group respectively ( Figure 6A&B ). In the high and low Tinf group, 392 the naïve cluster expressed MHC class II genes highly with a difference in CD24 expression ( Figure  393 6C&D, Supplementary Figure 6 ). Other clusters in both groups expressed BLIMP1 indicating they 394 are plasma cell clusters. In the high Tinf group, the BLIMP1 In this study, we characterized samples from 6 ovarian cancer patients. One to three sections of 402 tumors were processed to account for intratumor heterogeneity based on availability. Initial IHC 403 staining of these sections revealed a positive correlation between the area of tumor made up of 404 adipocytes and the number of immune cells within the tumor. We processed these tumor 405 sections and obtained Drop-seq data for a total of 9885 cells after quality control. Mapping our 406 cells to curated cell types from the CellAtlas along with gene ontology and pathway-based 407 enrichment was robust in assigning cells types to almost all clusters in our analysis. Our data also 408 revealed a positive correlation between the presence of adipocytes (by IHC) and immune cells 409 and stratified our patient cohort into two groups based on the intrinsic properties of the immune 410 response. 411 412
The largest cluster of cells was cancer epithelial cells, which composed about 50% of cells 413
analyzed. These cells expressed various genes associated with metastatic disease including 414 MUC16 and PAX8, consistent with previous reports. The gene expression matrix was similar 415 between cancer cells from each patient. The variety of cancer associated genes expressed by 416 these cancer cells confirm the compensatory mechanisms that continue to progress disease. 417
Another approach to suppressing tumor growth is by identifying and targeting cancer stem cell 418 (CSC) in ovarian cancer 47 . Like other studies, we were unable to identify cells that expressed 419 known makers of stem cells 48,49 . However, we identified a cell population closely resembling ESC 420 and connected to the epithelial cell cluster that highly expressed proliferative marker, Ki-67. In addition to the major cell types analyzed, there were other clusters including 3 undecideds 453 (N1, N2, N3), 1 endothelial, 1 mesenchymal stem cell and 1 fibroblast cluster. For the undecided 454 clusters, by mapping them to the CellAtlas cell types, they best correlate with astrocytes, 455 CMP/bone marrow progenitor and plasmacytoid dendritic cells respectively. We did not recover 456 adipocytes as they were probably lost during the tissue dissociation. Endothelial cells are the 457 major cell types involved in angiogenesis which is necessary for metastasis. The mesenchymal 458 stem cells are connected to the fibroblasts. Inflamed omentum contains stem cells displaying 459 similar surface markers to MSCs. These stem cells are capable of differentiating into fat, cartilage 460 or bone depending on the secreted factors present 55,56 . Finally, there was a significant fibroblast 461 cluster in our sample population. Metastatic transformation of the omentum changes the cellular 462 composition from mainly adipocytes to cancer cells, immune cells and fibroblasts 28 . Cancer 463 associated fibroblasts mainly function to remodel the extracellular matrix in the tumor 464 microenivironment 57 . Recently, a scRNA-seq study of CAF in pancreatic cancer revealed a 465 LRRC15 + CAF population that correlated with poor response in patients treated with anti-PD-L1 466 therapy 58 . A few of the fibroblasts in our study also express LRRC15 (data not shown). Ultimately, 467 more studies are needed to further elucidate these cells and how they can be manipulated to 468 enhance immunotherapeutic approaches. 469 470
Conclusion

472
To our knowledge, this is the first scRNA-seq study that allows stratification of patient samples 473 all initially pathologically classified as stage III, according to immune response in metastatic 474 ovarian cancer. Concurrent transcriptomic analysis of cancer and stromal cells revealed patient 475 heterogeneity highlighting the need for personalized medicine. Interrogating tumor infiltrating 476 lymphocytes at the single cell level also revealed patient-intrinsic responses that are previously 477 undescribed in ovarian cancer. Mechanistic studies are required to determine the role of these 478 cells in tumor progression and response to novel cancer immunotherapies. 479 480 Acknowledgment 481 482
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